Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: A phase II study

Anti-Cancer Drugs

Volumn 15, Issue 7, 2004, Pages 719-724

  Loibl, S ^a   Von Minckwitz, G ^a   Schwedler, K ^a   Schmidt, K A ^a   Hoper D ^b   Kaufmann, M ^a   Costa, S D ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c Klinik Bad Trissl   (Germany)

Author keywords

5 fluorouracil; Folinic acid; Liver dysfunction; Liver metastases; Metastatic breast cancer; Mitomycin C

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; HORMONE; LIVER ENZYME; MITOMYCIN C; ONDANSETRON; PREDNISONE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; FATIGUE; FEVER; HORMONAL THERAPY; HORMONE DEPENDENCE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; JAUNDICE; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER METASTASIS; LUNG TOXICITY; MEASUREMENT; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; THROMBOCYTOPENIA; TIME SERIES ANALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MIDDLE AGED; MITOMYCIN; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS;

EID: 4143151670     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000136692.99971.ec     Document Type: Article

References (26)

1. von Minckwitz G, Costa SD, Brunnert K, Dall P, Nitz U, Diel I, et al. Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast. Z Gynäkol 2002; 124:284-292.
2. Crown J, Dieras V, Kaufmann M, von Minckwitz G, Kaye S, Leonard R, et al. Chemotherapy for metastatic breast cancer - report of a European expert panel. Lancet Oncol 2002; 3:719-727.
3. Giordano SH, Buzdar AU, Kau S-W, Hortobagyi N. Improvement in breast survival: results from M. D. Anderson Cancer Center protocols from 1975-2000. Proc Am Soc Clin Oncol 2002; 21:54a (abstr 212).
4. Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000; 18:562-573.
5. Bartsch HH, Blossey HC, Nagel GA. Mitomycin C and high-dosage medroxyprogesterone acetate in the therapy of metastasizing breast cancer. Results of a phase II study of the Workshop for Internal Oncology of the German Cancer Association. Onkologie 1982; 5:249-257.
6. Riggs CE. Antitumor antibiotics and related compounds. In: Perry MC (editor): The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins; 1996, pp. 345-385.
7. von Hazel GA, Scott M, Rubin J, Moertel CG, Eagan RT, O'Connell MJ, et al. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 1983; 67:805-810.
8. Kennedy KA, Rockwell S, Sartorelli AC. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980; 40:2356-2360.
9. Francinci G, Petrioli R, Aquino A, Gonnelli S. Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. Cancer Chemother Pharmacol 1993; 32:359-364.
10. Koh DW, Castro A. Pulmonary toxicity of chemotherapeutic drugs. In: Perry MC (editor): The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins; 1996, pp. 665-695.
11. Agarwal K, Jones DE, Burt AD, Hudson M, James OF. Metastatic breast carcinoma presenting as acute liver failure and portal hypertension. Am J Gastroenterol 2002; 97:750-751.
12. Tomassini E, Muhizi J, al Raheb K, Steinbach G, Bemer M, Platini C. Fulminant hepatocellular necrosis following administration of docetaxel. Presse Med 2001; 30:634.
13. Feenstra J, Vermeer RJ, Stricker BH. Fatal hepatic coma attributed to paclitaxel. J Natl Cancer Inst 1997; 89:582-584.
14. Bruno R, Sanderink GJ. Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv 1993; 17:305-313.
15. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24:153-172.
16. Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy - efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 33:19-27.
17. Sharma RA, Decatris MP, Santhanam S, Roy R, Osman AE, Clarke CB, et al. Reversibility of liver failures secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemother Pharmacol 2003; 52:367-370.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-649.
19. Twelves C, Dobbs NA, Michael Y, Summers LA, Gregory W, Harper PG, et al. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 1992; 66:765-769.
20. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, et al. Effect of hepatic dysfuntion due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696-1702.
21. Spanswick VJ, Cummings J, Smyth JF. Current issues in the enzymology of mitomycin C metabolic activation. Gen Pharmacol 1998; 31: 539-544.
22. Jiang HB, Ichikawa M, Furukawa A, Tomita S, Ichikawa Y. Reductive activation of mitomycin C by neuronal nitric oxide synthase. Biochem Pharmacol 2000; 15:571-579.
23. Inagaki R, Taniguchi T, Sakai T, Hayashi N, Ishii Y, Muramatsu I. Anticancer drugs inhibit induction of NO synthase in rat in vivo. Gen Pharmacol 1999; 32:185-188.
24. Mattsson W, von Eyben F, Hallsten L, Bjelkengren G. A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer. Cancer 1982; 49:217-220.
25. Francinci G, Petrioli R, Messinese S, Prozzessere D, Marssili S, Correale P, et al. Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. Cancer Chemother Pharmacol 2002; 50:271-276.
26. Verweij J, van der Burg MEL, Pinedo HM. Mitomycin C induced hemolytic uremic syndrome: six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8:33-41.